Thyroid Cancer (Papillary, Follicular, and Hurthle Cell Carcinoma)

    Actionable Target Abnormality Prevalence (%) Clinical Experience with Targeted Agent
    BRAF (papillary) Mutation 52 Associated with more aggressive disease, particularly with presence of TERT promoter mutation Sorafenib (RAF/VEGFR inhibitor) (FDA approved):
    • Phase 3: PR 13%, SD 67%, PFS 10.8 mo(2)*
    Vemurafenib (BRAF inhibitor):
    • Phase 2: VEGFR naïve, PR 38.5%, SD 57.7%, PD 3.8%, PFS 18.2 mo; previous VEGFR treated, PR 27.3%, SD 63.6%, PD 4.5%, PFS 8.9 mo (3)
    Dabrafenib (BRAF inhibitor):
    • Phase 1: RR 33% (4)
    Selumetinib (MEK1/2 inhibitor):
    • Phase 2: PR 3%, SD 54% (5)
    Other topics in Targets by Organ Site